Literature DB >> 22908280

An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state.

Christos Polytarchou1, Dimitrios Iliopoulos, Kevin Struhl.   

Abstract

Cancer stem-like cells (CSCs) are a highly tumorigenic cell type present as a minority population in developmentally diverse tumors and cell lines. Using a genetic screen in an inducible model of CSC formation in a breast cell line, we identify microRNAs (miRNAs) that inhibit CSC growth and are down-regulated in CSCs. Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b. Interestingly, these miRNAs affect common target genes that encode the Bmi1 and Suz12 components of the polycomb repressor complexes as well as the DNA-binding transcription factors Zeb1, Zeb2, and Klf4. Conversely, expression of the CSC-modulating miRNAs is inhibited by Zeb1 and Zeb2. There is an inverse relationship between the levels of CSC-regulating miRNAs and their respective targets in samples from triple-negative breast cancer patients, providing evidence for the relevance of these interactions in human cancer. In addition, combinatorial overexpression of these miRNAs progressively attenuates the growth of CSCs derived from triple-negative breast cancers. These observations suggest that CSC formation and function are reinforced by an integrated regulatory circuit of miRNAs, transcription factors, and chromatin-modifying activities that can act as a bistable switch to drive cells into either the CSC or the nonstem state within the population of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22908280      PMCID: PMC3437881          DOI: 10.1073/pnas.1212811109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Polycomb complexes repress developmental regulators in murine embryonic stem cells.

Authors:  Laurie A Boyer; Kathrin Plath; Julia Zeitlinger; Tobias Brambrink; Lea A Medeiros; Tong Ihn Lee; Stuart S Levine; Marius Wernig; Adriana Tajonar; Mridula K Ray; George W Bell; Arie P Otte; Miguel Vidal; David K Gifford; Richard A Young; Rudolf Jaenisch
Journal:  Nature       Date:  2006-04-19       Impact factor: 49.962

2.  Control of developmental regulators by Polycomb in human embryonic stem cells.

Authors:  Tong Ihn Lee; Richard G Jenner; Laurie A Boyer; Matthew G Guenther; Stuart S Levine; Roshan M Kumar; Brett Chevalier; Sarah E Johnstone; Megan F Cole; Kyo-ichi Isono; Haruhiko Koseki; Takuya Fuchikami; Kuniya Abe; Heather L Murray; Jacob P Zucker; Bingbing Yuan; George W Bell; Elizabeth Herbolsheimer; Nancy M Hannett; Kaiming Sun; Duncan T Odom; Arie P Otte; Thomas L Volkert; David P Bartel; Douglas A Melton; David K Gifford; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2006-04-21       Impact factor: 41.582

3.  Suz12 binds to silenced regions of the genome in a cell-type-specific manner.

Authors:  Sharon L Squazzo; Henriette O'Geen; Vitalina M Komashko; Sheryl R Krig; Victor X Jin; Sung-wook Jang; Raphael Margueron; Danny Reinberg; Roland Green; Peggy J Farnham
Journal:  Genome Res       Date:  2006-06-02       Impact factor: 9.043

4.  Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10.

Authors:  H D Soule; T M Maloney; S R Wolman; W D Peterson; R Brenz; C M McGrath; J Russo; R J Pauley; R F Jones; S C Brooks
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

5.  IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis.

Authors:  Matjaz Rokavec; Weilin Wu; Jun-Li Luo
Journal:  Mol Cell       Date:  2012-02-23       Impact factor: 17.970

6.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

Authors:  Sun-Mi Park; Arti B Gaur; Ernst Lengyel; Marcus E Peter
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

Review 7.  Cancer stem cells in solid tumors.

Authors:  Laurie E Ailles; Irving L Weissman
Journal:  Curr Opin Biotechnol       Date:  2007-10       Impact factor: 9.740

8.  An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.

Authors:  Ittai Ben-Porath; Matthew W Thomson; Vincent J Carey; Ruping Ge; George W Bell; Aviv Regev; Robert A Weinberg
Journal:  Nat Genet       Date:  2008-05       Impact factor: 38.330

9.  Identification of tumorigenic retinal stem-like cells in human solid retinoblastomas.

Authors:  Xiufeng Zhong; Yongping Li; Fuhua Peng; Bing Huang; Jianxian Lin; Wenxin Zhang; Jianliang Zheng; Ruzhang Jiang; Ge Song; Jian Ge
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

10.  Endogenous human microRNAs that suppress breast cancer metastasis.

Authors:  Sohail F Tavazoie; Claudio Alarcón; Thordur Oskarsson; David Padua; Qiongqing Wang; Paula D Bos; William L Gerald; Joan Massagué
Journal:  Nature       Date:  2008-01-10       Impact factor: 49.962

View more
  64 in total

1.  Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.

Authors:  Javier A Menendez; Tomás Alarcón; Bruna Corominas-Faja; Elisabet Cuyàs; Eugeni López-Bonet; Angel G Martin; Luciano Vellon
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

2.  Leptin-STAT3-G9a Signaling Promotes Obesity-Mediated Breast Cancer Progression.

Authors:  Chao-Ching Chang; Meng-Ju Wu; Jer-Yen Yang; Ignacio G Camarillo; Chun-Ju Chang
Journal:  Cancer Res       Date:  2015-04-03       Impact factor: 12.701

Review 3.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 4.  Common stemness regulators of embryonic and cancer stem cells.

Authors:  Christiana Hadjimichael; Konstantina Chanoumidou; Natalia Papadopoulou; Panagiota Arampatzi; Joseph Papamatheakis; Androniki Kretsovali
Journal:  World J Stem Cells       Date:  2015-10-26       Impact factor: 5.326

5.  MicroRNAs, a subpopulation of regulators, are involved in breast cancer progression through regulating breast cancer stem cells.

Authors:  Xuemei Fan; Wei Chen; Ziyi Fu; Lihua Zeng; Yongmei Yin; Hongyan Yuan
Journal:  Oncol Lett       Date:  2017-09-01       Impact factor: 2.967

6.  MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy.

Authors:  Parwez Ahmad; Jiri Sana; Marek Slavik; Dominik Gurin; Lenka Radova; Natalia Anna Gablo; Tomas Kazda; Pavel Smilek; Zuzana Horakova; Bretislav Gal; Marketa Hermanova; Pavel Slampa; Ondrej Slaby
Journal:  Cancer Genomics Proteomics       Date:  2019 Mar-Apr       Impact factor: 4.069

7.  Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.

Authors:  Heather A Hirsch; Dimitrios Iliopoulos; Kevin Struhl
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-31       Impact factor: 11.205

Review 8.  Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells.

Authors:  Kirti S Prabhu; Afsheen Raza; Thasni Karedath; Syed Shadab Raza; Hamna Fathima; Eiman I Ahmed; Shilpa Kuttikrishnan; Lubna Therachiyil; Michal Kulinski; Said Dermime; Kulsoom Junejo; Martin Steinhoff; Shahab Uddin
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

9.  The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.

Authors:  Javier A Menendez; Jorge Joven; Sílvia Cufí; Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Begoña Martin-Castillo; Eugeni López-Bonet; Tomás Alarcón; Alejandro Vazquez-Martin
Journal:  Cell Cycle       Date:  2013-04-02       Impact factor: 4.534

Review 10.  MicroRNAs in cancer.

Authors:  Gianpiero Di Leva; Michela Garofalo; Carlo M Croce
Journal:  Annu Rev Pathol       Date:  2013-09-25       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.